Ubrelvy is a groundbreaking migraine medication that offers fast, effective relief for those suffering from acute migraine attacks. Developed by Allergan, now part of AbbVie, Ubrelvy (ubrogepant) is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine in adults. Unlike traditional migraine medications, Ubrelvy works by blocking CGRP, a protein believed to play a crucial role in migraine attacks. This innovative approach allows patients to find relief without the drowsiness or cardiovascular risks associated with some other migraine treatments. With its rapid onset of action and favorable safety profile, Ubrelvy is changing the landscape of migraine management, empowering patients to take control of their migraine symptoms and get back to their daily lives.
.png){kind=small}
